Holen Sie sich die Stockscreener-App
1.32
0.76%
0.01
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LXRX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.31
Offen:
$1.33
24-Stunden-Volumen:
1.23M
Relative Volume:
0.54
Marktkapitalisierung:
$479.69M
Einnahmen:
$1.21M
Nettoeinkommen (Verlust:
$-177.12M
KGV:
-1.65
EPS:
-0.8
Netto-Cashflow:
$-162.37M
1W Leistung:
-5.71%
1M Leistung:
-7.04%
6M Leistung:
+88.28%
1J Leistung:
+80.35%
1-Tages-Spanne:
$1.30
$1.3605
1-Wochen-Bereich:
$1.29
$1.4799
52-Wochen-Spanne:
$0.2836
$1.66
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Firmenname
Lexicon Pharmaceuticals Inc
Sektor
Branche
Telefon
(281) 863-3000
Adresse
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Vergleichen Sie LXRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.32 | 476.05M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-03-07 | Eingeleitet | Jefferies | Hold |
| 2022-08-12 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-01-29 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-18 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-12-11 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2019-11-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-11 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-07-29 | Herabstufung | Stifel | Buy → Hold |
| 2019-03-25 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2018-07-31 | Bestätigt | Stifel | Buy |
| 2018-02-23 | Herabstufung | Needham | Buy → Hold |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-03-01 | Bestätigt | H.C. Wainwright | Buy |
| 2017-03-01 | Bestätigt | Wedbush | Outperform |
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-08-05 | Bestätigt | Wedbush | Outperform |
| 2016-08-02 | Eingeleitet | Citigroup | Buy |
| 2016-03-02 | Bestätigt | Wedbush | Outperform |
| 2015-11-09 | Bestätigt | Wedbush | Outperform |
| 2015-09-28 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2015-09-18 | Herabstufung | Gabelli & Co | Hold → Sell |
| 2015-08-10 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten
Novo Nordisk (NVO) Collaborates with Lexicon on Obesity Treatmen - GuruFocus
Lexicon Pharmaceuticals Publishes Preclinical Data Supporting ACSL5 as Target for Obesity Treatment - Quiver Quantitative
Lexicon Pharmaceuticals (Nasdaq: LXRX) publishes ACSL5 obesity data supporting LX9851 - Stock Titan
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Clinical data on effect of sotagliflozin on adipose distribution in non-diabetic patients - marketscreener.com
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum - The Manila Times
Clinical Data On Effect Of Sotagliflozin On Adipose Distribution In Non-Diabetic Patients - TradingView
Lexicon Pharmaceuticals to Present Clinical Data on Sotagliflozin at CVCT 2025 Conference - Quiver Quantitative
Lexicon Pharmaceuticals, Inc. (LXRX) Makes Progress in Product Pipeline Development - MSN
Is Lexicon Pharmaceuticals Inc. stock attractive for ETFs2025 Key Highlights & Daily Profit Maximizing Trade Tips - Newser
Year in Review: Local co. striking deal worth up to $1B with Ozempic maker was a Deal of the Week - The Business Journals
Carcinoid Syndrome Market to Expand Significantly by 2034, - openPR.com
Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well - Seeking Alpha
Piper Sandler Healthcare Conference - marketscreener.com
Lexicon Pharmaceuticals (LXRX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Crosses Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Will Lexicon Pharmaceuticals Inc. stock deliver long term returns2025 Market Overview & Fast Entry High Yield Stock Tips - BỘ NỘI VỤ
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences - The Manila Times
Lexicon Pharma (Nasdaq: LXRX) in Piper Sandler 37th and Evercore 8th investor events - Stock Titan
Would You Still Hold Lexicon Pharmaceuticals Stock If It Fell 30%? - Trefis
10 Fastest Growing Penny Stocks to Buy Now - Insider Monkey
Why Lexicon Pharmaceuticals Inc. stock is considered a top pick2025 Stock Rankings & Daily Market Momentum Tracking - newser.com
Can Lexicon Pharmaceuticals Inc. stock deliver consistent earnings growthWeekly Trend Recap & Reliable Intraday Trade Plans - newser.com
Will Lexicon Pharmaceuticals Inc. stock split attract more investorsBear Alert & Daily Price Action Insights - newser.com
Can Lexicon Pharmaceuticals Inc. stock resist market sell offs2025 Institutional Moves & Weekly Watchlist for Hot Stocks - newser.com
Can Lexicon Pharmaceuticals Inc. stock surprise with earnings upsideQuarterly Market Review & Accurate Buy Signal Notifications - newser.com
Transcript : Lexicon Pharmaceuticals, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 05 - MarketScreener
Is Lexicon Pharmaceuticals Inc. stock attractive for growth ETFs2025 Earnings Surprises & Verified Technical Trade Signals - newser.com
How to manage a losing position in Lexicon Pharmaceuticals Inc.Analyst Upgrade & Verified Entry Point Signals - newser.com
Lexicon Pharmaceuticals at Jefferies London: Strategic Pipeline Progress By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals at Jefferies London: Strategic Pipeline Progress - Investing.com
Xpeng, Dell And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
Published on: 2025-11-16 06:10:48 - newser.com
Wall Street Zen Downgrades Lexicon Pharmaceuticals (NASDAQ:LXRX) to Hold - MarketBeat
Lexicon Pharmaceuticals: A Lottery Ticket With 3 Chances To Win (NASDAQ:LXRX) - Seeking Alpha
Lexicon Pharmaceuticals backs Type 1 diabetes research ahead of World Diabetes Day - Traders Union
What the charts say about Lexicon Pharmaceuticals Inc. todayTake Profit & Real-Time Chart Breakout Alerts - newser.com
What MACD signals say about Lexicon Pharmaceuticals Inc.July 2025 Earnings & Fast Moving Stock Watchlists - newser.com
Private Equity Firms in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 17% Last Week - 富途牛牛
Broker Revenue Forecasts For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Are Surging Higher - Yahoo Finance
Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):